As shown in Fig. 7, GAT107 caused a significant reduction in the secretion of both IL-6 and IL-17: IL-17 secretion was decreased by 11% in HDs and 18% in MS patients, and a similar decrease was observed after treatment with ACh (7% in HDs and 13% in MS patients). Here, IL6 is linked to myeloid sarcoma.